GRFS and Octapharma, BAX's competitors in IVIG, are not waiting around to see if Gammagard works for AD in phase-3. Rather, they have started their own AD trials—see #msg-50841315 and #msg-49232696.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”